{"corpus_id":6743454,"paper_sha":"3db870999a3a0b7ec9466118419f040ec7a2c20d","doi":"10.1001/JAMA.288.1.49","arxiv_id":null,"pmid":12090862,"pmcid":null,"mag_id":2113259481,"dblp_id":null,"acl_id":null,"title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).","year":2002,"publication_date":"2002-07-03","venue":"Journal of the American Medical Association (JAMA)","journal":{"name":"JAMA","pages":"\n          49-57\n        ","volume":"288 1"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":74,"citation_count":1911,"influential_citation_count":44,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aspirin","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D001241"},{"d":"Coronary Disease","mj":false,"qs":[{"q":"epidemiology","mj":true,"ui":"Q000453"},{"q":"prevention & control","mj":false,"ui":"Q000517"}],"ui":"D003327"},{"d":"Estrogen Replacement Therapy","mj":true,"ui":"D015914"},{"d":"Estrogens, Conjugated (USP)","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D004966"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Follow-Up Studies","mj":false,"ui":"D005500"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D019161"},{"d":"Medroxyprogesterone Acetate","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D017258"},{"d":"Myocardial Infarction","mj":false,"qs":[{"q":"epidemiology","mj":false,"ui":"Q000453"}],"ui":"D009203"},{"d":"Postmenopause","mj":false,"ui":"D017698"},{"d":"Risk Factors","mj":false,"ui":"D012307"},{"d":"Survival Analysis","mj":false,"ui":"D016019"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"}],"chemicals":[{"n":"Estrogens, Conjugated (USP)","ui":"D004966","reg":"0"},{"n":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","ui":"D019161","reg":"0"},{"n":"Medroxyprogesterone Acetate","ui":"D017258","reg":"C2QI4IOI2G"},{"n":"Aspirin","ui":"D001241","reg":"R16CO5Y76E"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"CONTEXT: The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized trial of estrogen plus progestin therapy after menopause. OBJECTIVE: To examine the effect of long-term postmenopausal hormone therapy on common noncardiovascular disease outcomes. DESIGN AND SETTING: Randomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent open-label observational follow-up for 2.7 years (HERS II), carried out between 1993 and 2000 in outpatient and community settings at 20 US clinical centers. PARTICIPANTS: A total of 2763 postmenopausal women with coronary disease and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II. INTERVENTION: Participants were randomly assigned to receive 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 1380) or placebo (n = 1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II. The proportions with at least 80% adherence to hormones declined from 81% (year 1) to 45% (year 6) in the hormone group and increased from 0% (year 1) to 8% (year 6) in the placebo group. MAIN OUTCOME MEASURES: Thromboembolic events, biliary tract surgery, cancer, fracture, and total mortality. RESULTS: Comparing women assigned to hormone therapy with those assigned to placebo, the unadjusted intention-to-treat relative hazard (RH) for venous thromboembolism declined from 2.66 (95% confidence interval [CI], 1.41-5.04) during HERS to 1.40 (95% CI, 0.64-3.05) during HERS II (P for time trend =.08); it was 2.08 overall for the 6.8 years (95% CI, 1.28-3.40), and 3 of the 73 women with thromboembolism died within 30 days due to pulmonary embolism. The overall RH for biliary tract surgery was 1.48 (95% CI, 1.12-1.95); for any cancer, 1.19 (95% CI, 0.95-1.50); and for any fracture, 1.04 (95% CI, 0.87-1.25). There were 261 deaths among those assigned to hormone therapy and 239 among those assigned to placebo (RH, 1.10; 95% CI, 0.92-1.31). Adjusted and as-treated analyses did not alter our conclusions. CONCLUSIONS: Treatment for 6.8 years with estrogen plus progestin in older women with coronary disease increased the rates of venous thromboembolism and biliary tract surgery. Trends in other disease outcomes were not favorable and should be assessed in larger trials and in broader populations.","claims":[{"public_id":"cl_05f4986aa2dfd17215fd7fcc15baedb2","status":"active","text":"Estrogen plus progestin therapy did not show favorable trends for cancer, fracture, or total mortality outcomes in this population.","confidence":0.86,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_05f4986aa2dfd17215fd7fcc15baedb2"},{"public_id":"cl_735478bed91649244c9fedb20cad6883","status":"active","text":"The overall relative hazard for biliary tract surgery was 1.48 for women assigned to hormone therapy compared with placebo.","confidence":0.94,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_735478bed91649244c9fedb20cad6883"},{"public_id":"cl_96ddb0f5cae80434d5d257921778a70c","status":"active","text":"The randomized HERS trial and subsequent HERS II follow-up evaluated long-term postmenopausal hormone therapy among 2763 postmenopausal women with coronary disease at 20 US clinical centers.","confidence":0.93,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_96ddb0f5cae80434d5d257921778a70c"},{"public_id":"cl_c429f7f81c59bfbef9a5ff8424e6702f","status":"active","text":"The unadjusted intention-to-treat relative hazard for venous thromboembolism was 2.08 overall during 6.8 years for women assigned to hormone therapy compared with placebo.","confidence":0.95,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_c429f7f81c59bfbef9a5ff8424e6702f"},{"public_id":"cl_05f6166f9383e233027d747942dc8135","status":"active","text":"Treatment for 6.8 years with estrogen plus progestin in older postmenopausal women with coronary disease increased rates of venous thromboembolism and biliary tract surgery.","confidence":0.98,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_05f6166f9383e233027d747942dc8135"}],"concepts":[{"public_id":"co_2e54393af8b452128270bfef64507f9d","status":"active","name":"estrogen plus progestin therapy","description":"A postmenopausal treatment using conjugated estrogens plus medroxyprogesterone acetate in this trial.","types":["intervention"],"aliases":["hormone therapy"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_2e54393af8b452128270bfef64507f9d"},{"public_id":"co_41059efd0d5c30ca8990846ea3e31f5a","status":"active","name":"total mortality","description":"The outcome counting deaths among participants assigned to hormone therapy or placebo.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_41059efd0d5c30ca8990846ea3e31f5a"},{"public_id":"co_4a55975a551ec98804bbb1f4066397ca","status":"active","name":"HERS II","description":"The open-label observational follow-up phase conducted after the Heart and Estrogen/progestin Replacement Study.","types":["observational follow-up"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_4a55975a551ec98804bbb1f4066397ca"},{"public_id":"co_5ba3feb41875a9a1be125f6aec16a88e","status":"active","name":"any fracture","description":"A fracture outcome category assessed among participants during follow-up.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_5ba3feb41875a9a1be125f6aec16a88e"},{"public_id":"co_6f2c1839811ecdb45197c56b6e7a94c4","status":"active","name":"postmenopausal women with coronary disease","description":"The participant population enrolled in HERS, with an average age of 67 years at enrollment.","types":["participant population"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_6f2c1839811ecdb45197c56b6e7a94c4"},{"public_id":"co_770539fbbbf0fd732c76963c6256db70","status":"active","name":"placebo","description":"The inactive comparison assignment used during the randomized HERS trial.","types":["control intervention"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_770539fbbbf0fd732c76963c6256db70"},{"public_id":"co_795406bd2ec7b8bf1bae86cc3635ab72","status":"active","name":"Heart and Estrogen/progestin Replacement Study","description":"A randomized, blinded, placebo-controlled trial of estrogen plus progestin therapy after menopause.","types":["clinical trial"],"aliases":["HERS"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_795406bd2ec7b8bf1bae86cc3635ab72"},{"public_id":"co_a66f5de22ef9ab43f20c0b994acfc0bc","status":"active","name":"biliary tract surgery","description":"A surgical outcome involving the biliary tract that was measured during follow-up.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_a66f5de22ef9ab43f20c0b994acfc0bc"},{"public_id":"co_a844176735303cb26ac46c9b31df0eec","status":"active","name":"intention-to-treat relative hazard","description":"A comparative hazard measure based on randomized assignment, reported for study outcomes.","types":["statistical measure"],"aliases":["RH"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_a844176735303cb26ac46c9b31df0eec"},{"public_id":"co_bc76ca9a295a9f53b4f6dd74e2620405","status":"active","name":"any cancer","description":"A cancer outcome category assessed among participants during follow-up.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_bc76ca9a295a9f53b4f6dd74e2620405"},{"public_id":"co_ee3c85098bc112d655e8beca47efa09f","status":"active","name":"venous thromboembolism","description":"A thromboembolic event outcome measured during HERS and HERS II follow-up.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_ee3c85098bc112d655e8beca47efa09f"}],"external_ids":{"DOI":"10.1001/JAMA.288.1.49","ArXiv":null,"PubMed":12090862,"PubMedCentral":null,"MAG":2113259481,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/6743454","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631764,"paper_uid":"6cc2fc79-7f75-4660-9d09-32869cc19fd7","canonical_identity":{"paper_id":631764,"paper_uid":"6cc2fc79-7f75-4660-9d09-32869cc19fd7","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/6743454"}